Abstract

Opioid-induced respiratory depression presents a critical challenge in clinical settings, characterized by reduced respiratory rate and depth due to central nervous system depression and impaired respiratory muscle function. This condition is exacerbated by factors such as opioid potency, route of administration, and patient-specific vulnerabilities. Early signs include drowsiness and shallow breathing, progressing to severe respiratory compromise if untreated. Effective management involves vigilant monitoring of respiratory parameters and prompt intervention with naloxone, supplemented by oxygen therapy and advanced airway management as needed. Healthcare providers must prioritize risk assessment, continuous monitoring, and education to mitigate risks and optimize patient outcomes. This abstract provides a concise overview of the mechanisms, risk factors, and management strategies essential for addressing opioid-induced respiratory depression in clinical practice.